Safety and Efficacy of Intravesical Gentamicin for Recurrent Urinary Tract Infections and/or Catheter Blockages
Authors:
- 12 March 2026
- journal article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 45 (4) , 681-688
Abstract
Aims: To assess the safety and efficacy of intravesical gentamicin in patients with recurrent urinary tract infections (UTI) and/or catheter blockages. Methods: This prospective, single‐center study enrolled adult patients with recurrent UTIs and/or catheter blockages who had been prescribed intravesical gentamicin (once‐daily, 30−60 mL, 0.48 mg/mL, held 60 min) from June 1, 2024, to April 1, 2025. Eligible patients had received ≥ 14 days' intravesical gentamicin. Primary outcomes were, for patients with recurrent UTIs, subjective (patient‐reported) and objective (positive culture with symptoms) rates of UTI per 12‐month‐equivalent, before versus during treatment. Results: Fifty‐five patients were prescribed intravesical gentamicin, of whom 42 were eligible. Median age was 58 years, and 26 patients (62%) were female. Thirty‐six patients (86%) had neurogenic bladder, and 38 (90%) had pre‐existing catheter use (suprapubic: 17; intermittent: 15; indwelling urethral: six). Median follow‐up was 6 months. Compared with pre‐treatment, patients experienced significantly fewer subjective (median 6.5 vs. 0; p < 0.00001) and objective (median 5.5 vs. 0; p < 0.00001) UTIs per 12‐month‐equivalent. Regarding secondary outcomes, for patients with recurrent UTIs, gentamicin was associated with decreased rates of UTI‐related emergency department presentations per 12‐month‐equivalent (median 1 vs. 0; p = 0.005) and decreased proportion of patients with ≥ 1 multi‐drug‐resistant UTI (70% vs. 23%; p = 0.00002). Median ease‐of‐use was 4/5, and likelihood‐to‐recommend was 5/5. Complications were reported by 11 patients (26%), all Clavien−Dindo Grade I. Of patients with prior catheter blockages, 47% reported decreased catheter blockages, although duration between catheter changes was unchanged (median 28 vs. 28 days; p = 0.53). Conclusions: Intravesical gentamicin appears safe and effective prophylaxis for recurrent UTIs and/or catheter blockages. Trial Registration: This study has been registered with the Australian New Zealand Clinical Trials Registry, submission 389972.Keywords
This publication has 37 references indexed in Scilit:
- The Effects of Gentamicin Intravesical Bladder Instillations on Decreasing Urinary Tract Infections After Spinal Cord Injury and DiseaseNeurourology and Urodynamics, 2025
- Is Intravesical Gentamicin the New Gold Standard to Manage Refractory Urinary Tract Infections?—Experience From a Dedicated Multidisciplinary Complex UTI ClinicNeurourology and Urodynamics, 2024
- Effectiveness and patient perspective on the use of intravesical gentamicin instillations to treat recurrent urinary tract infections in neurogenic lower urinary tract dysfunctionNeurourology and Urodynamics, 2024
- Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic ReviewCurrent Urology Reports, 2018
- Complications of Spinal Cord Injury Over the First Year After Discharge From Inpatient RehabilitationArchives of Physical Medicine and Rehabilitation, 2017
- The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunctionNeurourology and Urodynamics, 2017
- Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patientsNeurourology and Urodynamics, 2013
- Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims databaseNeurourology and Urodynamics, 2010
- Intravesical instillation of gentamicin sulfate: In vitro, rat, canine, and human studiesUrology, 1994
- Prophylaxis of urinary tract infection in persons with recent spinal cord injury: A prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazoleThe American Journal of Medicine, 1993